Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Hepatitis drugs show promise in battle against COVID-19

IANS
Updated: August 26th, 2020, 06:37 IST
in Feature
0
(PTI)

(PTI)

Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

New research adds to the growing body of evidence that sofosbuvir and daclatasvir, a drug combination commonly used for the treatment of hepatitis C, can improve clinical outcomes in patients with moderate or severe COVID-19.

Three studies, published in Journal of Antimicrobial Chemotherapy, researched the use of sofosbuvir and daclatasvir for the treatment of COVID-19.

Also Read

Indian railways viral news

‘My brother is a loco pilot’: Ticketless passenger argues, makes ‘casteist remark’ at TTE

3 days ago
Viral video

Video: Man tortures, kills 2-month-old puppy in Delhi, gets community justice in return

3 days ago

These three studies come from Iran, which has developed its own pill containing sofosbuvir and daclatasvir, and is in a position to test this in a large clinical trial as Iran is a massively impacted country, reporting some 2,500 cases and 200 deaths a day.

“Despite the encouraging initial results, it is too early to reach a verdict. Larger, well-designed studies are required to confirm our results,” said Shahin Merat, the lead author of one of the Journal of Antimicrobial Chemotherapy articles, from Tehran University in Iran.

Currently no effective antiviral therapy has been found to treat COVID-19. The aim of the trials was to assess if the addition of sofosbuvir and daclatasvir, a drug combination commonly used for the treatment of hepatitis C, improved clinical outcomes in patients with moderate or severe COVID-19.

In one trial, researchers recruited 66 patients and allocated them to either the treatment group or the control group. The study found that clinical recovery within 14 days was achieved by 88 per cent in the treatment group and 67 per cent in the control group. The treatment group had a significantly shorter median duration of hospitalisation (six days) than the control group (eight days).

In another study, subjects suffering from Covid-19 were divided into two groups with one group receiving ribavirin and the other receiving sofosbuvir/daclatasvir. All participants also received the recommended national standard treatment which, at that time, was lopinavir/ritonavir and single-dose hydroxychloroquine.

The results indicated that the median duration of stay was five days for the sofosbuvir/daclatasvir group and nine days for the ribavirin group. The mortality in the sofosbuvir/daclatasvir group was six per cent and 33 per cent for the ribavirin group. The relative risk of death for patients treated with sofosbuvir/daclatasvir was 0.17 per cent.

The results of these studies suggest that the addition of sofosbuvir and daclatasvir to standard care may reduce the duration of hospital stays for COVID-19 patients compared to standard care alone.

Earlier, a study published in the journal The Lancet, found that hepatitis C virus drugs may be effective in treating patients with COVID-19.

(IANS)

Tags: COVID-19Hepatitis
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Ankita Balabantray

December 12, 2019
#MyPaperBagChallenge

Aman Kumar Barisal

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Adweeti Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Sisirkumar Maharana

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Faiza Firdous

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Narendra Kumar

December 12, 2019
#MyPaperBagChallenge

Rajashree Pravati Mohanty

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Smitarani Sahoo

December 12, 2019
#MyPaperBagChallenge

Matrumangal Jena

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Ipsita

December 12, 2019

Archives

Editorial

Peacemakers

Trump-Maria
October 14, 2025

There is rejoicing as peace has started to return to the heart of the war-ravaged Middle East, and a ceasefire...

Read moreDetails

Afghanistan As Friend

Afghanistan
October 13, 2025

Some politicians and feminists are screaming that it is outrageous that the Taliban could display its misogyny on Indian soil...

Read moreDetails

Stalled Promise

October 12, 2025

Thirty five years ago, India chose to go down two paths, on both of which it remains. The first path...

Read moreDetails

Trade to Tirade

October 11, 2025

It started, as many big stories do these days, with a tweet. A blunt social media post by a mid-sized...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST